Access the full text.
Sign up today, get DeepDyve free for 14 days.
Davide Franchina, Catherine Dostert, D. Brenner (2018)
Reactive Oxygen Species: Involvement in T Cell Signaling and Metabolism.Trends in immunology, 39 6
R. Jenkins, D. Barbie, K. Flaherty (2018)
Mechanisms of resistance to immune checkpoint inhibitorsBritish Journal of Cancer, 118
O. Demaria, S. Cornen, M. Daëron, Y. Morel, R. Medzhitov, É. Vivier (2019)
Harnessing innate immunity in cancer therapyNature, 574
K. Chamoto, P. Chowdhury, Alok Kumar, K. Sonomura, F. Matsuda, S. Fagarasan, T. Honjo (2017)
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activityProceedings of the National Academy of Sciences, 114
P. Zhang, J. Miska, C. Lee-Chang, Aida Rashidi, Wojciech Panek, S. An, M. Zannikou, Aurora Lopez-Rosas, Yu Han, Ting Xiao, Katarzyna Pituch, Deepak Kanojia, I. Balyasnikova, M. Lesniak (2019)
Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastomaProceedings of the National Academy of Sciences, 116
Jingchao Li, D. Cui, Jiaguo Huang, Shasha He, Zebin Yang, Yan Zhang, Yu Luo, Kanyi Pu (2019)
Organic Semiconducting Pro-nanostimulants for Near-Infrared Photoactivatable Cancer Immunotherapy.Angewandte Chemie
Vivek Verma, R. Shrimali, Shamim Ahmad, Winjie Dai, Hua Wang, Sumin Lu, Rahul Nandre, Pankaj Gaur, Jose Lopez, Moshe Sade-Feldman, Keren Yizhak, Stacey Bjorgaard, K. Flaherty, J. Wargo, G. Boland, R. Sullivan, G. Getz, S. Hammond, M. Tan, J. Qi, P. Wong, T. Merghoub, J. Wolchok, N. Hacohen, J. Janik, M. Mkrtichyan, Seema Gupta, S. Khleif (2019)
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistanceNature Immunology, 20
S. Ganesh, Xue Shui, Kevin Craig, Jihye Park, Weimin Wang, B. Brown, M. Abrams (2018)
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint BlockadeMolecular Therapy, 26
A. Weert, H. Geuze, B. Groothuis, W. Stoorvogel (2000)
Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes.European journal of cell biology, 79 6
A. Schoenfeld, M. Hellmann (2020)
Acquired Resistance to Immune Checkpoint Inhibitors.Cancer cell, 37 4
P. Sharma, S. Hu-Lieskovan, J. Wargo, A. Ribas (2017)
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 168
Jia Yu, J. Hodge, C. Oliva, Svetoslav Neftelinov, Vanessa Hubbard-Lucey, Jun Tang (2019)
Trends in clinical development for PD-1/PD-L1 inhibitorsNature Reviews Drug Discovery, 19
Limo Chen, L. Diao, Yongbing Yang, X. Yi, B. Rodriguez, Y. Li, Y. Li, P. Villalobos, T. Cascone, Xi Liu, L. Tan, P. Lorenzi, Anfei Huang, Qiang Zhao, Di Peng, Jared Fradette, D. Peng, Christin Ungewiss, Jonathon Roybal, P. Tong, Junna Oba, F. Skoulidis, W. Peng, B. Carter, Youhong Fan, Caleb Class, Jingfen Zhu, J. Rodriguez-Canales, Masanori Kawakami, L. Byers, S. Woodman, V. Papadimitrakopoulou, E. Dmitrovsky, Jing Wang, S. Ullrich, I. Wistuba, J. Heymach, F. Qin, F. Qin, D. Gibbons (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.Cancer discovery, 8 9
T. Gide, J. Wilmott, R. Scolyer, G. Long (2017)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic MelanomaClinical Cancer Research, 24
B. Allard, D. Allard, L. Buisseret, J. Stagg (2020)
The adenosine pathway in immuno-oncologyNature Reviews Clinical Oncology
Ryan Setten, J. Rossi, Si-ping Han (2019)
The current state and future directions of RNAi-based therapeuticsNature Reviews Drug Discovery, 18
M. Sanmamed, Lieping Chen (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to NormalizationCell, 175
N. Restifo, M. Smyth, A. Snyder (2016)
Acquired resistance to immunotherapy and future challengesNature Reviews Cancer, 16
Yan Lyu, Shasha He, Jingchao Li, Yuyan Jiang, He Sun, Yansong Miao, Kanyi Pu (2019)
Photolabile Semiconducting Polymer Nanotransducer for Near-infrared Regulation of CRISPR/Cas9 Gene Editing.Angewandte Chemie
A. Palmer, P. Sorger (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or SynergyCell, 171
Dipti Vijayan, A. Young, M. Teng, M. Smyth (2017)
Targeting immunosuppressive adenosine in cancerNature Reviews Cancer, 17
D. Schmid, Chun Park, Christina Hartl, Nikita Subedi, Adam Cartwright, Regina Puerto, Yiran Zheng, James Maiarana, G. Freeman, K. Wucherpfennig, D. Irvine, Michael Goldberg (2017)
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunityNature Communications, 8
S. Topalian, J. Taube, D. Pardoll (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapyScience, 367
J. Galon, Daniela Bruni (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapiesNature Reviews Drug Discovery, 18
D. Cui, Jingchao Li, Xuhui Zhao, Kanyi Pu, Ruiping Zhang (2019)
Semiconducting Polymer Nanoreporters for Near‐Infrared Chemiluminescence Imaging of ImmunoactivationAdvanced Materials, 32
Lawrence Andrews, H. Yano, D. Vignali (2019)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backupsNature Immunology, 20
Bowen Yang, Yu Chen, Jianlin Shi (2019)
Reactive Oxygen Species (ROS)-Based Nanomedicine.Chemical reviews, 119 8
S. Wei, Jacob Levine, Alexandria Cogdill, Yang Zhao, Nana-Ama Anang, M. Andrews, P. Sharma, Jing Wang, J. Wargo, D. Pe’er, J. Allison (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 170
M. Burr, C. Sparbier, Yih-Chih Chan, J. Williamson, K. Woods, P. Beavis, E. Lam, M. Henderson, Charles Bell, Sabine Stolzenburg, O. Gilan, S. Bloor, T. Noori, D. Morgens, M. Bassik, P. Neeson, A. Behren, P. Darcy, S. Dawson, I. Voskoboinik, J. Trapani, J. Cebon, P. Lehner, M. Dawson (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityNature, 549
(2017)
39, 489; b)
Daixi Ren, Yuze Hua, Boyao Yu, Xin Ye, Ziheng He, Chunwei Li, Jie Wang, Yongzhen Mo, Xiaoxu Wei, Yunhua Chen, Yujuan Zhou, Q. Liao, Hui Wang, Bo Xiang, Ming Zhou, Xiaoling Li, Gui-yuan Li, Yong Li, Zhaoyang Zeng, W. Xiong (2020)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapyMolecular Cancer, 19
Douglas Johnson, Mellissa Nixon, Yu Wang, Daniel Wang, E. Castellanos, M. Estrada, P. Ericsson-Gonzalez, Candace Cote, R. Salgado, V. Sanchez, Phillip Dean, S. Opalenik, D. Schreeder, D. Rimm, Ju Kim, J. Bordeaux, S. Loi, L. Horn, M. Sanders, P. Ferrell, Yaomin Xu, J. Sosman, Randall Davis, J. Balko (2018)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.JCI insight, 3 24
S. Koyama, Esra Akbay, Yvonne Li, G. Herter-Sprie, Kevin Buczkowski, W. Richards, L. Gandhi, A. Redig, S. Rodig, H. Asahina, Robert Jones, Meghana Kulkarni, M. Kuraguchi, Sangeetha Palakurthi, P. Fecci, B. Johnson, P. Jänne, J. Engelman, Sidharta Gangadharan, D. Costa, G. Freeman, R. Bueno, F. Hodi, G. Dranoff, Kwok-kin Wong, P. Hammerman, P. Hammerman (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNature Communications, 7
Greta Garrido, B. Schrand, A. Rabasa, A. Levay, Francesca D’Eramo, A. Berezhnoy, S. Modi, T. Gefen, K. Marijt, E. Doorduijn, V. Dudeja, T. Hall, E. Gilboa (2019)
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunityNature Communications, 10
A. Ribas, J. Wolchok (2018)
Cancer immunotherapy using checkpoint blockadeScience, 359
G. Shayan, Raghvendra Srivastava, Jing Li, N. Schmitt, L. Kane, R. Ferris (2017)
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancerOncoImmunology, 6
Zecong Xiao, Zhenwei Su, Shisong Han, Jinsheng Huang, Liteng Lin, X. Shuai (2020)
Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapyScience Advances, 6
Acquired resistance (AR) resulted from stimulated expression of AR‐related genes such as CD38 in activated T cells jeopardizes anti‐programmed death‐1 (anti‐PD‐1) immunotherapy. It remains to be explored whether the suppression of AR genes in activated T cells during anti‐PD‐1 therapy is able to overcome AR and improve the efficacy of immunotherapy. Small‐interfering RNAs (siRNAs) acting via RNA interference mechanisms are able to shut down the expression of target genes. The authors report here a T‐cell targeting conjugate of antibody‐siRNA with response to reactive oxygen species (ROS) (TCARROS) for the suppression of AR gene as well as to block the PD‐1/PD‐L1 interaction. TCARROS is able to bind with PD‐1 on T cells, then release functional siRNA to suppress AR genes in activated T cells with abundant ROS to cleave the linker in the conjugate. TCARROS comprising the siRNA targeting CD‐38 attached to PD‐1 blocking antibody (αPD‐1) via the ROS responsive linker is tested on activated T cells as well as mice bearing B16 tumor. Synergistic effect is observed on mice treated with TCARROS in anti‐PD‐1 immunotherapy, which suggests the potentials of this novel ROS responsive αPD‐1‐siRNA conjugate in anti‐PD‐1 immunotherapy to overcome AR.
Advanced Therapeutics – Wiley
Published: Jan 1, 2022
Keywords: acquired resistance; antibody‐siRNA conjugate; cancer immunotherapy; CD38; PD‐1; T cell
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.